T1	Participants 103 153	patients with advanced non-small-cell lung cancer.
T2	Participants 226 284	patients with advanced non-small-cell lung cancer (NSCLC).
T3	Participants 461 728	Between January 1995 and April 1996, 414 patients with stage IIIB or IV NSCLC were randomized to received either a control arm of high-dose cisplatin (100 mg/m(2)) or a combination of paclitaxel (175 mg/m(2), 3-hour infusion) and cisplatin (80 mg/m(2)) every 21 days.
